Premium
Prospective trial of chemotherapy‐enhanced accelerated radiotherapy for larynx preservation in patients with intermediate‐volume hypopharyngeal cancer
Author(s) -
Kawashima Mitsuhiko,
Hayashi Ryuichi,
Tahara Makoto,
Arahira Satoko,
Miyazaki Masakazu,
Sakuraba Minoru,
Zenda Sadamoto,
Ogino Takashi
Publication year - 2012
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21934
Subject(s) - medicine , hypopharyngeal cancer , head and neck cancer , radiation therapy , larynx , regimen , surgery , chemotherapy , prospective cohort study , cisplatin , adverse effect , dose fractionation
Background Altered fractionation radiotherapy (RT) improves locoregional control in head and neck cancer without aggravation of late adverse events. To improve successful larynx‐preservation rates in patients with resectable, intermediate‐volume hypopharyngeal cancer, a prospective trial of chemotherapy‐enhanced accelerated RT was conducted. Methods Patients with T2 to T4 hypopharyngeal cancer received 40 Gray (Gy)/4 weeks to the entire neck followed by boost RT administering 30 Gy/2 weeks (1.5 Gy twice‐daily fractionation). Cisplatin and 5‐fluorouracil were administered concomitantly only during boost RT. Results Thirty‐five patients were enrolled in this study. All patients completed this protocol as planned. After a median follow‐up period for surviving patients of 59 months (24–90 months), overall survival and local control rates at 3 years were 91% (95% confidence interval, 81% to 100%), and 88% (79% to 99%), respectively. All surviving patients maintained normalcy of diets. Conclusion This regimen was feasible with encouraging oncological and functional outcomes. © 2011 Wiley Periodicals, Inc. Head Neck, 2011